Xinda biology and adimab cooperate to develop therapeutic antibody
-
Last Update: 2020-04-03
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
On August 20, Cinda biopharmaceutical (Suzhou) Co., Ltd announced that it has signed a development and commercialization plan for therapeutic antibody with adimab company of the United States The main terms of the scheme are: adimab develops therapeutic antibodies against targets selected by Cinda by using its antibody discovery and optimization platform If the development is successful, Cinda will be responsible for commercialization in China, and adimab will be responsible for commercialization in the United States, Europe and Japan Adimab can use yeast to synthesize therapeutic antibodies It has signed target discovery agreements with Merck, Roche, Novartis, Lilly, celgene, Genentech, Novo Nordisk, Gillette and GlaxoSmithKline Interestingly, two yeast engineering companies, adimab and glycofi Since the sale of glycofi to Merck for $400 million, the founding team left, established adimab, and got Google's venture capital Cinda bio pharmaceutical is invested by Fidelity Investment Group and Lilly pharmaceutical.
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
